Treatment of severe hypertension during pregnancy: we still do not know what the best option is

Dagmar Wertaschnigg*, Rui Wang, Maya Reddy, Fabricio Da Silva Costa, Ben Willem J. Mol, Daniel L. Rolnik

*Corresponding author for this work

Research output: Contribution to journalReview article

Abstract

Intracranial hemorrhage and stroke are primary causes of maternal mortality in pregnancies affected by hypertensive disorders. As such antihypertensive therapy plays a crucial role in the management of severe hypertension. However, the target level to achieve the best outcome for both–mother and fetus–is still unclear. Moreover, given the lack of well-designed randomized controlled trials with standardized key outcomes, the current choice of antihypertensive medications depends rather on clinicians’ preference. Furthermore, data on long-term outcomes of offspring is not available. Therefore, there is an urgent need for randomized trials comparing different anti-hypertensive options to address efficacy and safety questions.

Original languageEnglish
Pages (from-to)25-32
Number of pages8
JournalHypertension in Pregnancy
Volume39
Issue number1
Early online date27 Dec 2019
DOIs
Publication statusPublished - 2 Jan 2020

Keywords

  • key outcome parameters
  • maternal and perinatal morbidity
  • pre-eclampsia
  • Severe hypertension in pregnancy
  • target blood pressure
  • DIAGNOSIS
  • TRIALS
  • MANAGEMENT
  • SEVERE PREECLAMPSIA
  • GUIDELINES
  • DISORDERS
  • CLASSIFICATION
  • LABETALOL
  • HYDRALAZINE
  • NIFEDIPINE

Fingerprint Dive into the research topics of 'Treatment of severe hypertension during pregnancy: we still do not know what the best option is'. Together they form a unique fingerprint.

  • Cite this